Transcription factor decoy approach to decipher the role of NF-κB in oncogenesis

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 61-70

  Sharma, Harsh W ^a   Perez, Jose R ^a   Higgins Sochaski, Kimberley ^a   Hsiao, Rongshen ^a   Narayanan, Ramaswamy ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antisense; DNA binding; Phosphorothioate; RelA; Tumor cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOROTHIOIC ACID; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; COLONIC NEOPLASMS; DNA, NEOPLASM; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; SP1 TRANSCRIPTION FACTOR; THIONUCLEOTIDES; TRANSCRIPTION FACTOR RELA;

EID: 0029980617     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Grilli M, Chiu JS and Lenardo MJ: NF-κB and Rel - participants in a multiform transcriptional regulatory system. Int Rev Cytol 143: 1-62, 1993.
2. Nolan GP, Ghosh S, Liou HC, Tempst P and Baltimore D: DNA binding and IKB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 64: 961-969, 1991.
3. Bose HR Jr: The Rel family: Models for transcriptional regulation and oncogenic transformation. Biochim Biophys Acta 1114: 1-17, 1992.
4. Gilmore TD: Role of rel family genes in normal and malignant lymphoid cell growth. Cancer Surv 15 69, 1992
5. Kunsch C, Ruben SM, and Rosen CA: Selection of optimal κB/Rel DNA binding motifs: Interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol Cell Biol 12: 4412-4421, 1992.
6. Sharma HW, Higgins-Sochaski KA, Perez JR and Narayanan R: A DNA motif present in αV integrin promoter exhibits dual binding preference to distinct transcription factors. Anticancer Res 15: 1857-1868, 1995.
7. Baeuerle PA and Henkel T: Function and activation of NF-κB in the immune system Annu Rev Immunol 12: 141-179, 1994.
8. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R: Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes turnor regression. Proc Natl Acad Sci USA 90: 9901-9905, 1993.
9. Narayanan R, Higgins KA, Perez JR, Coleman TA, and Rosen CA: Evidence for differential functions of the p50 and p65 subunits of NF-κB using a cell adhesion model. Mol Cell Biol 13: 3802-3810, 1993.
10. Narayanan R: The NF-κB transcription factor in oncogenesis. Crit Rev Onc Hem 1996. (In Press)
11. Perez JR, Higgins-Sochaski KA, Maltese JY, and Narayanan R: Regulation of adhesion and growth of fibrosarcoma cells by rel A NF-κB involves TGF.B. Mol Cell Biol 14. 5326-5332, 1994.
12. Narayanan R, Schaapveld RQ, Cho KR, Vogelstein B, Tran PB, Osborne MP and Telang NT: Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7: 553-561, 1992.
13. Goldring CE, Narayanan R, Lagadec P and Jeannin JF: Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-κB/Rel proteins. Biochem Biophys Res Commun 209: 73-79, 1995.
14. Himes SR, Coles LS, Katsikeros R, Lang RK, and Shannon MF: HTLV-1 tax activation of the GM-CSF and G-CSF promoters requires the interaction of NF-κB with other transcription factor families. Oncogene 8, 3189-3197, 1993.
15. Dunn SM, Coles LS, Lang RK, Gerondakis S, Vadas MA and Shannon MF: Requirement for nuclear factor (NF)-κB p65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood 83: 2469-2479, 1994.
16. Perez JR, Li Y, Stein CA, Majumder S, van Oorschot A and Narayanan R: Sequence independent induction of Sp-1 transcription factor by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 97: 5957-5961, 1994.
17. Stein CA and Cheng YC: Antisense oligonucleotides as therapeutic agents - Is the bullet Really Magical? Science 261: 1004-1012, 1993.
18. Stein CA and Narayanan R: Antisense oligonucleotides. Curr Opin Oncol 6: 587-594, 1994.
19. Sharma HW and Narayanan R: The therapeutic potential of antisense oligodeoxynucleotides. BioEssays 17: 1055-1063, 1995.
20. Sokoloski JA, Sartorelli AC, Rosen CA and Narayanan R: Antisense oligonucleotides to the p65 subunit of NF-κB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood 82: 625-632, 1993.
21. Narayanan R: Antisense therapy of cancer. In Vivo 8: 787-794, 1994.
22. Kitajima I, Shinohara T, Bilakovics I, Brown DA, Xu X, and Nerenberg M: Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 258: 1792-1795, 1992.
23. Eck SL, Perkins ND, Carr DP and Nabel GJ: Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-κB in vivo. Mol Cell Biol 13: 6530-6536, 1993.
24. Yaswen P, Stampfer MR, Ghosh K, and Cohen JS: Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3: 67-77, 1993.
25. Maltese JY, Vassilev L, Sharma HW, and Narayanan R: Sequence context of antisense RelA/NF-κB phosphorothioates determines specificity. Nucleic Acids Res 7: 1146-1151, 1995.
26. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T and Dzau VJ: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92: 5855-5859, 1995.